CRBP
Corbus Pharmaceuticals Holdings, Inc.
stockNASDAQ
corbus pharmaceuticals holdings, inc. (nasdaq: crbp) is a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases with clear unmet needs. the company's lead product candidate, resunab™, is a first-in-class, oral anti-inflammatory drug that acts to resolve inflammation through an endogenous pathway. resunab is scheduled to commence three phase 2 clinical trials in 2015 for the treatment of cystic fibrosis, diffuse systemic sclerosis ("scleroderma") and dermatomyositis, three diseases in which inflammation contributes to disease progression. resunab also has the potential to treat additional rare, inflammatory diseases.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 6.92 | 2026-09-28 | -11.34% | -3.384 |
| 1M | 11.08 | 2026-09-04 | -44.63% | 2.353 |
| 3M | 9.00 | 2026-07-06 | -31.83% | 1.317 |
| 6M | 10.14 | 2026-04-06 | -39.50% | 1.303 |
| 1Y | 14.52 | 2025-10-06 | -57.75% | 1.133 |
| 2Y | 19.21 | 2024-10-04 | -68.06% | — |
| 5Y | 30.90 | 2021-10-05 | -80.15% | 1.315 |
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) stock price today is $6.14, and today's volume is 835,403. CRBP is down 3.233% today. The 30 day average volume is 1.16M. CRBP market cap is $118.66M with 19.34M shares outstanding.